Raf-1 Kinase and Exoenzyme S Interact with 14-3-3zeta through a Common Site Involving Lysine 49*

(Received for publication, December 12, 1996, and in revised form, March 12, 1997)

Lixin Zhang Dagger §, Haining Wang §, Dong Liu par , Robert Liddington ** and Haian Fu Dagger Dagger Dagger

From the Dagger  Department of Pharmacology and the  Graduate Program of Cell and Developmental Biology, Emory University School of Medicine, Atlanta, Georgia 30322, the par  Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, and the ** Department of Biochemistry, University of Leicester, Leicester LE1 7RH, United Kingdom

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

14-3-3 proteins are a family of conserved dimeric molecules that bind to a range of cellular proteins involved in signal transduction and oncogenesis. Our solution of the crystal structure of 14-3-3zeta revealed a conserved amphipathic groove that may allow the association of 14-3-3 with diverse ligands (Liu, D., Bienkowska, J., Petosa, C., Collier, R. J., Fu, H., and Liddington, R. (1995) Nature 376, 191-194). Here, the contributions of three positively charged residues (Lys-49, Arg-56, and Arg-60) that lie in this Raf-binding groove were investigated. Two of the charge-reversal mutations greatly (K49E) or partially (R56E) decreased the interaction of 14-3-3zeta with Raf-1 kinase, whereas R60E showed only subtle effects on the binding. Interestingly, these mutations exhibited similar effects on the functional interaction of 14-3-3zeta with another target protein, exoenzyme S (ExoS), an ADP-ribosyltransferase from Pseudomonas aeruginosa. The EC50 values of 14-3-3zeta required for ExoS activation increased by ~110-, 5-, and 2-fold for the K49E, R56E, and R60E mutants, respectively. The drastic reduction of 14-3-3zeta /ligand affinity by the K49E mutation is due to a local electrostatic effect, rather than the result of a gross structural alteration, as evidenced by partial proteolysis and circular dichroism analysis. This work identifies the first point mutation (K49E) that dramatically disrupts 14-3-3zeta /ligand interactions. The parallel effects of this single point mutation on both Raf-1 binding and ExoS activation strongly suggest that diverse associated proteins share a common structural binding determinant on 14-3-3zeta .


INTRODUCTION

14-3-3 proteins are a family of dimeric eukaryotic molecules involved in diverse cellular processes (see Ref. 1 for review). They were originally identified as brain-specific proteins (2) and later found to be present in most mammalian tissues as well as in other eukaryotic organisms, including yeast and plants. Members of the 14-3-3 family have been highly conserved throughout evolution (>60% identity between yeast and mammalian isoforms), reflecting the fundamental importance of 14-3-3 proteins in cellular physiology. Indeed, deletion of the two isoforms of yeast 14-3-3 is lethal to both Saccharomyces cerevisiae and Schizosaccharomyces pombe (3-5).

Multiple biochemical activities have been ascribed to the 14-3-3 family of proteins, although the precise function of 14-3-3 in cellular regulation is unclear. They have been shown to activate tyrosine and tryptophan hydroxylases (6, 7) and are involved in the regulation of protein kinase C activity (8-10). In vitro, 14-3-3 directly activates a bacterial ADP-ribosyltransferase, exoenzyme S (ExoS),1 from Pseudomonas aeruginosa (11). Because of its specificity and sensitivity, activation of ExoS has been used as a simple functional assay for the presence of 14-3-3 proteins (12). Recently, members of the 14-3-3 protein family were found to associate with a number of proto-oncogene and oncogene products (13) as well as with proteins involved in apoptosis. These 14-3-3-associated proteins include Raf kinases (12, 14-16), Bcr and Bcr-Abl (17), Cdc25 phosphatases (18), phosphatidylinositol 3-kinase (19), Cbl (20), the middle tumor antigen of polyoma virus (21), A20 (22), and Bad (23). Through protein/protein interactions, 14-3-3 may regulate diverse cellular processes.

The 14-3-3/Raf interaction has been extensively studied because of the central importance of Raf kinases in mitogenic signal transduction. Both in vivo and in vitro experimental data strongly support a biologically relevant interaction of 14-3-3 with Raf kinases. For instance, overexpression of either the yeast homologue, BMH1, or mammalian 14-3-3 stimulates the biological activity of mammalian Raf in budding yeast (14, 15). Additionally, microinjection of 14-3-3 mRNA into Xenopus oocytes promotes Raf-dependent oocyte maturation (16). Raf immunoprecipitates from yeast or oocytes in the above experiments have increased kinase activity. However, when Raf kinase activity is measured directly with purified 14-3-3 in vitro, no activation of Raf can be demonstrated (12, 24, 25). Consistent with this, Dent et al. (26) found that 14-3-3 proteins can block the dephosphorylation and inactivation of Raf kinase by phosphatases in vitro. Recent demonstration of oligomerization-induced Raf activation suggests an intriguing role of 14-3-3 in promoting Raf dimerization/oligomerization during the activation process (27, 28) because it is possible for one dimeric 14-3-3 molecule to bind two Raf kinase molecules (29, 30). A negative role of 14-3-3 in Raf regulation has also been postulated based on the observation that Raf-1 mutants unable to stably interact with 14-3-3 exhibit enhanced kinase activity in mammalian cells and Xenopus oocytes and are biologically activated (31). However, it remains elusive how 14-3-3 proteins contribute to Raf signaling pathways.

To understand the biological consequence of the 14-3-3/Raf interaction in vivo, it is important to determine the key residues of 14-3-3 required for Raf binding. Defined point mutants will provide essential tools for dissecting the role of 14-3-3 proteins in Raf activation and in cellular regulation in general. Toward this goal, we have solved the three-dimensional crystal structure of the zeta -isoform of the 14-3-3 proteins (30). In the structure, each monomer of the dimeric protein consists of a bundle of nine alpha -helices organized in an antiparallel fashion. The four N-terminal alpha -helices participate in dimer formation. When viewed along the mean helix axis, the bundle of helices, alpha -helices 3-9, form a palisade. Residues that are conserved among members of the 14-3-3 family line the inside of this palisade and define a conserved groove. Not surprisingly, 14-3-3 proteins are also conserved at the tertiary structural level. The structure of 14-3-3tau (29) exhibits a very similar folded conformation to the zeta -isoform, and this should facilitate the identification of common residues of 14-3-3 required for ligand binding. Inspection of the surface property of the conserved groove of the 14-3-3zeta monomer reveals an amphipathic structure that is lined with charged residues on one side and hydrophobic residues on the other (30). Based on the fact that 14-3-3 proteins bind to a wide range of cellular partners, it is possible that this conserved groove of 14-3-3zeta is involved in ligand binding.

To test the crystal structure model, we set about to systematically analyze the contribution of individual residues in the amphipathic groove to ligand binding. Here, we report the identification of the first point mutation (K49E) of 14-3-3 proteins that disrupts the association of 14-3-3zeta with Raf-1 kinase and diminishes its ability to activate ExoS. The impaired binding is not due to gross alteration of the mutant 14-3-3zeta protein based on our partial proteolysis and CD analysis. The concomitant effects of a single point mutation on both Raf binding and ExoS activation strongly suggest that diverse ligands may share a common site on 14-3-3 proteins and that Lys-49 may represent a general site for ligand binding.


MATERIALS AND METHODS

Cell Growth Conditions and DNA Manipulations

Escherichia coli strains were grown routinely at 37 °C in LB broth or on LB agar plates (15 g/l). Ampicillin was used as required at a concentration of 100 µg/ml. Strain XL1-Blue (Stratagene, La Jolla, CA) was used for the propagation of plasmids, and strain BL21(DE3) was used for expression of proteins using bacteriophage T7 promoter-based overexpression vectors (32). S. cerevisiae strains were grown at 30 °C either in rich medium or in synthetic medium supplemented with relevant amino acids and 2% glucose or galactose as a carbon source (33). Minipreparation of plasmids, restriction enzyme digestion, subcloning procedures, cell transformation, and other molecular biology procedures were performed essentially as described (33) or as indicated. Double-stranded DNA sequencing was performed using Sequenase Version 2.0 (Amersham Corp.). Restriction enzymes and other molecular biology reagents were obtained from New England Biolabs Inc. (Beverly, MA), Promega (Madison, WI), and Life Technologies, Inc.

Plasmids

General Vectors

pHAF625 is a pUC19-based shuttle vector for 14-3-3zeta subcloning. The DNA sequence encoding 14-3-3zeta was amplified by polymerase chain reaction using pHAF612 (11) as a template. The following primers were used to introduce required restriction sites for the subsequent in-frame fusion constructions: 5'-GTCAAGAGGGAATTCCATATGGATAAAAACGAGCTG-3' (EcoRI and NdeI sites underlined) and 5'-CGTATAGAATTCGTCGACTCATTAATTTTCCCCTCC-3' (EcoRI and SalI sites underlined). The amplified DNA fragments were digested with EcoRI and subcloned into pUC19 at the EcoRI site with the 14-3-3zeta gene in the opposite orientation of lacZ. To introduce appropriate restriction sites for in-frame fusion of various versions of Raf-1 kinase, we constructed three basic Raf vectors. For this purpose, Raf sequences were amplified by polymerase chain reaction with added restriction sites using a full-length raf gene as a template (33). The following primers were used: 1) 5'-GGATCCGAATTCCATATGGAGCACATACAG-3' (EcoRI and NdeI sites underlined), 2) 5'-CAGGGTACCATCGATCTATGGTGCCCGCTCTCT-3' (ClaI site underlined), 3) 5'-CATATGGAATTCGTATCTGGGACCCAG-3' (EcoRI site underlined), and 4) 5'-CAGGGTACCATCGATCTAGAAGACAGGCAG-3' (ClaI site underlined). Primer pairs 1/4, 1/2, and 3/4 were used to amplify the full-length sequence of the Raf-1 kinase and the N-terminal (Raf-N, residues 1-320) and C-terminal (Raf-C, residues 321-648) fragments, respectively. These polymerase chain reaction fragments were digested with EcoRI and ClaI and subcloned into pKS(+) (Stratagene), generating pHW102 (Raf-1), pHW103 (Raf-N), and pHW105 (Raf-C). The integrity of the polymerase chain reaction sequences was verified by sequencing.

Vectors for Yeast Two-hybrid/Interaction Trap System

Parental vectors for the interaction trap system were kind gifts from Dr. Roger Brent (Harvard Medical School) and included pEG202 and pJG4-5 (34). pEG202 carries the sequence encoding the DNA-binding domain of the bacterial LexA protein, the expression of which is under the control of the ADH promoter. pJG4-5 carries the B42 transcriptional activation sequence fused to a nuclear localization sequence under the control of a GAL1 promoter. An epitope tag (influenza virus hemagglutinin) was inserted between the nuclear localization sequence and the sequence of interest to enable surveillance of the expressed fusion protein by immunoblotting. For studying 14-3-3zeta /Raf interaction, the wild-type 14-3-3zeta sequence and its mutant derivatives (EcoRI-SalI fragments; see description below) were obtained from pHAF625 and subcloned into either pEG202 (EcoRI-SalI sites) or pJG4-5 (EcoRI-XhoI sites), generating in-frame fusion constructs. Similarly, the EcoRI-SalI fragments of pHW102, pHW103, and pHW105 were ligated to the LexA sequence in pEG202, generating pHW107 (LexA-Raf-1), pHW108 (LexA-Raf-N), and pHW110 (LexA-Raf-C), and to the B42 sequence in pJG4-5, generating pHW112 (B42-Raf-1), pHW113 (B42-Raf-N), and pHW115 (B42-Raf-C), respectively.

Expression Vectors

For protein expression in E. coli, the NdeI-EcoRI fragments of pHAF625 encoding the mutant 14-3-3zeta proteins (see below) were subcloned into NdeI-EcoRI-cut pET-15b (Novagen, Madison, WI), generating pLZ121 (K49E), pHW167 (K49L), pHW168 (K49Q), pHW169 (K49R), pLZ125 (R56E), and pLZ126 (R60E).

Site-directed Mutagenesis

Oligonucleotide-directed mutagenesis was performed with double-stranded plasmid as the starting material according to the unique site elimination method (35). Two primers were used in this process, a mutagenic primer containing a desired mutation and a selection primer containing a mutation that eliminated a unique SspI site in pHAF625 (5'-AAATGCTTCAATGATATCGAAAAAGGAAG-3'; a new EcoRV site was introduced (underlined)). To facilitate the screening of the desired mutations and based on the degeneracy of the codons, restriction sites were purposely introduced into the mutagenic primers. The incorporation of the mutagenic primers was screened by restriction enzyme digestion, and the introduced mutations were verified by sequencing. The mutagenic primers used are listed below (mutations generated with the corresponding oligonucleotides are underlined, and the SacI sites introduced for screening are in lower-case letters): 1) 5'-GCTTATGAAAATGTTGTAGgagctcGTAGGTC-3' (Lys-49 to Glu); 2) 5'-GTTGCTTATCTAAATGTTGTAGgagctcGTAGG-3' (Lys-49 to Leu); 3) 5'-GCTTATCAAAATGTTGTAGgagctcGTAGG-3' (Lys-49 to Gln); 4) 5'-GCTTATAGAAATGTTGTAGgagctcGTAGG-3' (Lys-49 to Arg); 5) 5'-GTAGgagctcGTGAGTCATCTTGG-3' (Arg-56 to Glu); and 6) 5'-GTAGgagctcGTAGGTCATCTTGGGAGGTCGTCTC-3' (Arg-60 to Glu).

Yeast Two-hybrid/Interaction Trap Assay

A modified version of the yeast two-hybrid system (36), the interaction trap (34), was used for studying 14-3-3zeta /Raf interactions in vivo (33). S. cerevisiae EGY48 (MATa trp1 ura3 his3 LEU2::pLexAop6LEU2) was used as a host for all interaction experiments. Both pSH18-34 and pJK103 were used as reporters. pSH18-34 directs expression of a GAL1-lacZ gene from eight high affinity ColE1 LexA operators, whereas pJK103 uses two ColE1 LexA operators. For the protein/protein interaction analysis, EGY48 harboring a lacZ reporter was cotransformed with pEG202 derivatives and pJG4-5 derivatives by the lithium acetate method (33). Transformants were maintained in synthetic medium with glucose (2%) under selection for the URA3, HIS3, and TRP1 markers. Colonies were patched onto synthetic medium plates containing galactose (2%), raffinose (1%), and X-gal (Gold Biotechnology, Inc., St. Louis, MO) to induce and detect the expression of the lacZ reporter gene. The time required for color development of positive interactions on X-gal selection plates ranged from 8 to 24 h.

Assay of beta -Galactosidase Activity

For the quantitative liquid assay, yeast transformants were grown overnight in the appropriate synthetic selecting medium with glucose to A600 ~ 1.0. Cells were washed with and transferred to the galactose induction medium with 1% raffinose. After 12 h of induction, cells were prepared in fresh Z buffer and permeabilized using three drops of chloroform and two drops of 0.1% SDS as described (33). For quantitation, chlorophenyl-red-beta -D-galactopyranoside (Boehringer Mannheim) was added as a chromogenic substrate. The amount of liberated chlorophenol red was determined by A574, and the specific activity in Miller units was calculated based on the following equation: unit = (A574/(A600 × V × T)) × 1000, where A600 is the cell density used, V is the volume of the culture in ml, and T is the reaction time in min. Three independent colonies were used for each activity determination.

Protein Expression and Purification

Single colonies from LB/ampicillin plates, freshly streaked with E. coli BL21(DE3) harboring pET-15b-derived plasmids expressing 14-3-3zeta or its mutant derivatives, were transferred into 3-ml cultures of LB/ampicillin. These cultures were fermented overnight at 37 °C on a rotary wheel. On the second day, 2-liter flasks, each containing 250 ml of LB/ampicillin, were inoculated with the 3-ml overnight culture. The flasks were aerated on a rotary shaker (300 rpm; Innova 4000, New Brunswick Scientific, Edison, NJ) at 37 °C. The cultures were induced with isopropyl-beta -D-thiogalactopyranoside (1 mM) when A600 reached ~0.5. The cells were harvested after 4 h, immediately chilled, and centrifuged at 4000 × g for 15 min at 4 °C. The pellets were washed once with Tris/EDTA buffer (pH 8.0).

For the in vitro binding assay, the pellets were resuspended in ice-cold sonication buffer composed of 50 mM Na2HPO4 (pH 8.0), 100 mM KCl, 0.1% Tween 20, 1.0 mM phenylmethylsulfonyl fluoride, and 1.0 mM EDTA. The resuspended pellets were sonicated four times on ice for 20 s each using a Branson 450 Sonifier cell disruptor, with the power control at 3 and the duty cycle at 50%. Cellular debris was pelleted by centrifugation at 13,000 × g for 10 min at 4 °C. The supernatants were used as the source of hexahistidine-tagged 14-3-3zeta . For the purpose of protein purification, crude extracts were made as described above, except that the sonication buffer contained 20 mM Tris-HCl (pH 7.9), 500 mM NaCl, 5 mM imidazole, and 1 mM phenylmethylsulfonyl fluoride. Subsequently, wild-type 14-3-3zeta and its mutant derivatives were purified using Ni2+ chelating chromatography essentially as described (11). Hexahistidine tags were removed by thrombin digestion (0.5 unit/mg of proteins). The 14-3-3 proteins used for the quantitative assays were further purified by gel filtration chromatography (Superdex 200) in a Pharmacia FPLC system.

Solid-phase Binding Experiments

For the in vitro binding assays, hexahistidine-tagged 14-3-3zeta proteins in the crude extracts were incubated with Ni2+-charged Sepharose 6B beads (Novagen) for 1 h at 4 °C. Radiolabeled Raf-1 proteins were generated using the TNT in vitro transcription-translation system (Promega). The DNA template (pKS(+)-Raf-1) was incubated with TNT rabbit reticulocyte lysates in the presence of [35S]methionine (final concentration, 0.8 µCi/ml) for 90 min at 30 °C according to the manufacturer's specifications. For the binding assays, the immobilized 14-3-3zeta proteins (~5 µg each) were mixed with 35S-labeled Raf-1 in Nonidet P-40 buffer (1% Nonidet P-40, 137 mM NaCl, 1 mM MgCl2, and 40 mM Tris-HCl (pH 8.0)) for 1 h at 4 °C with rotation. The 14-3-3zeta complexes were extensively washed with Nonidet P-40 buffer three times, followed by radioimmune precipitation assay wash (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 137 mM NaCl, and 20 mM Tris-HCl (pH 8.0)) three times, and boiled for 3 min in SDS sample buffer before resolution by SDS-PAGE (12.5%). The presence of the radiolabeled products in the 14-3-3zeta complexes was visualized using a PhosphorImager (Molecular Dynamics, Inc.).

ExoS Activation Assay

The NAD+:SBTI ADP-ribosyltransferase assay measures the rate of incorporation of the [32P]ADP-ribose moiety of NAD+ into the trichloroacetic acid-precipitable SBTI fraction of the reaction mixture. SBTI is used as an artificial substrate, and the assays were performed essentially as described previously (11, 37). The reaction mixtures contained (in a final volume of 25 µl) 0.2 M sodium acetate (pH 6.0), 20 nM purified ExoS, 30 µM SBTI, 30 µM [adenylate-32P]NAD+, 1.5 µM bovine serum albumin, and varying concentrations of 14-3-3zeta or its mutant proteins. After 30 min at 25 °C, reactions were stopped by removing 15 µl of the reaction mixture, which was directly pipetted onto trichloroacetic acid-saturated filter paper. The filter pads were placed immediately into ice-cold trichloroacetic acid solution (5%) and washed three to five times by gentle agitation on a platform rocker until no counts could be detected in the discarded wash solutions. The filter pads were then washed twice for 5 min each in ice-cold methanol, dried, and counted with 3 ml of liquid scintillation mixture in a Beckman LS6500 scintillation counter. Incorporation of ADP-ribose into SBTI was calculated based on the increase in counts (minus background) with <20% of the reactants having been utilized. Activities were obtained from at least three separate experiments, each performed in duplicate. Data are expressed as pmol of ADP-ribose incorporated per min/pmol of ExoS. To verify the specific incorporation of the ADP-ribose into SBTI, 5 µl of the reaction mixtures were loaded onto an SDS-polyacrylamide (12.5%) gel and visualized using autoradiography. The amount of 32P incorporated specifically into SBTI was quantified using a PhosphorImager with Image Quant software (Molecular Dynamics, Inc.) and was found to be comparable to that obtained with the liquid assay described above. ExoS activation data were fit to the following equation using SigmaPlot (Jandel Scientific): v = Vmax[A]/(EC50 + [A]), where Vmax is the maximal activation expressed as pmol of ADP-ribose incorporated per min/pmol of ExoS, v is the observed enzyme activity, EC50 is the concentration of 14-3-3 proteins giving half-maximal activation, and [A] is the 14-3-3 concentration.

Protein Stability Assays

Partial Proteolytic Digestion

WT 14-3-3zeta and its mutant derivatives (2.5 µg) were incubated with 0.5 unit of chymotrypsin in a final volume of 10 µl at 37 °C for 30 min. Digested fragments were resolved by SDS-PAGE (15%), and the digestion patterns of the WT and mutant proteins were visualized using Silver Stain Plus (Bio-Rad).

CD Spectroscopy

The far-UV CD spectra were recorded on a Jasco 600 spectropolarimeter. Results are expressed as mean residue molar ellipticity ([theta ], degree·cm2·dmol-1) calculated from the following equation: [theta ] = ([theta ]obs × MRW)/(10 × L × C), where [theta ]obs is the observed ellipticity expressed in millidegree, MRW is the mean residue molecular weight (114 for 14-3-3zeta ), L is the optical path length in cm (0.1 cm), and C is the final protein concentration in mg/ml. Far-UV CD spectra were the average of four scans obtained by collecting data at 0.2-nm intervals from 250 to 190 nm with a protein concentration of 0.4 mg/ml in phosphate-buffered saline. For the guanidine hydrochloride denaturation experiments, changes in the helical content of the sample were monitored at 222 nm. Phosphate-buffered saline was used for these studies. The half-melting concentration (Cm) is defined as the concentration of denaturant at the midpoint of the transition. The breadth of the transition (Delta C) is defined as the difference in denaturant concentrations between the points at which the transition is one-fourth and three-fourths complete.

SDS-PAGE and Immunoblotting

An SDS-PAGE system was used essentially as described by Laemmli (38). The enzyme-linked immunoblotting procedures of Towbin et al. (39) were followed. Proteins separated by SDS-PAGE were electrophoretically transferred to nitrocellulose membranes and incubated with antiserum (1:2000 dilutions for mouse anti-hemagglutinin monoclonal antibody (BAbCO, Richmond, CA)). Cross-reacting materials were visualized with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G using ECL (Amersham Corp.).

Protein Assay

Protein concentration was estimated by the Bio-Rad protein assay kit based on the method of Bradford (40), and bovine serum albumin was used as the standard.


RESULTS

Crystal Structure of 14-3-3zeta Suggests the Participation of Charged Residues in Ligand Binding

In the three-dimensional crystal structure of 14-3-3zeta , we identified a conserved amphipathic groove that may represent a general site for binding to associated proteins (Fig. 1) (30). On the charged face of the groove, exposed residues Lys-49, Arg-56, and Arg-60 are lined along alpha -helix 3. The side chains of these three positively charged residues project toward the inside of the groove, which positions the charged groups of the side chains well for potential contact with charged groups from the interacting ligand. As a first step in the systematic dissection of residues of 14-3-3 involved in ligand binding, we examined the contributions of these three positively charged residues to 14-3-3 protein/protein associations.


Fig. 1. Atomic model (solid sphere representation) of the 14-3-3 monomer. The figure was prepared using the program GRASP (53) and shows the amphipathic groove and the residues lining the groove (Lys-49, Arg-56, and Arg-60) that were mutated in this study.
[View Larger Version of this Image (97K GIF file)]

Mutations of Lys-49, Arg-56, and Arg-60 Decrease the Binding of 14-3-3zeta to Raf-1 Kinase

To test whether charged residues in the proposed groove are involved in ligand binding, we made three charge-reversal mutations by site-directed mutagenesis, generating K49E, R56E, and R60E (Fig. 1). It has been established that 14-3-3zeta directly binds to Raf-1 kinase in vivo and in vitro (13). Individual mutations were tested for their effect on the interaction of 14-3-3zeta with Raf-1 kinase.

We used the interaction trap to determine the 14-3-3zeta /Raf interaction in an in vivo environment (34). Raf-1 was fused to the DNA-binding domain of LexA protein, whereas 14-3-3zeta was fused to the B42 transcriptional activation sequence as described under "Materials and Methods." Interaction between the LexA-Raf-1 and B42-14-3-3 fusion proteins results in transcription of a lacZ reporter and consequently beta -galactosidase activity that can be visualized using chromogenic substrates (X-gal). Initially, the X-gal plate assay was performed to assess the relative interactions of 14-3-3zeta and Raf in various combinations. Consistent with previous reports (14-16), expression of 14-3-3zeta and Raf-1 induced the production of beta -galactosidase activity (Table I), reflecting the interaction of 14-3-3zeta with Raf-1 in yeast. No beta -galactosidase activity was detectable when LexA-Raf or B42-14-3-3zeta fusion protein was expressed independently. Introduction of the charge-reversal mutations K49E and R56E abolished beta -galactosidase production, suggesting decreased binding of 14-3-3zeta to Raf-1. The mutation R60E had no significant effect on the 14-3-3zeta /Raf interaction in this assay. It has been demonstrated that 14-3-3 binds to both the N-terminal regulatory fragment of Raf-1 and the C-terminal kinase domain (12, 14-16, 25). Consistent with these reports, cotransformation of yeast with WT 14-3-3zeta and either the N- or C-terminal sequence of Raf-1 induced blue colony formation (Table I). Interestingly, the K49E and R56E mutations diminished the interaction of 14-3-3zeta with both the N- and C-terminal domains. This result suggests that the N- and C-terminal fragments of Raf-1 associate with 14-3-3zeta via a similar site on 14-3-3zeta and that 14-3-3zeta can interact with the N- or C-terminal fragment of Raf-1 independently. To rule out possible reporter effects (41), two types of lacZ reporters were used for the above experiments: a sensitive reporter, pSH18-34 (with eight operators for LexA binding), and a less sensitive reporter, pJK103 (with two operators). Similar results were obtained with each (data not shown).

Table I. Interactions of Raf-1 kinase with WT and mutant 14-3-3zeta proteins analyzed by two-hybrid assay

Versions of the pEG202 expression plasmids producing LexA DNA-binding domain fusion proteins or derivatives of pJG4-5 vectors that encode B42 transactivation domain fusion proteins were introduced into the yeast host EGY48 harboring the reporter pSH18-34. The resulting transformants were grown on synthetic plates containing glucose, and six colonies each were patched onto plates containing galactose, raffinose, and X-gal. The galactose-dependent production of blue-colored patches is indicated as +, whereas white patches are indicated as -. This plate assay is used only for qualitative purposes. A less sensitive reporter, pJK103, was also tested and essentially gave similar results. Versions of the pEG202 expression plasmids producing LexA DNA-binding domain fusion proteins or derivatives of pJG4-5 vectors that encode B42 transactivation domain fusion proteins were introduced into the yeast host EGY48 harboring the reporter pSH18-34. The resulting transformants were grown on synthetic plates containing glucose, and six colonies each were patched onto plates containing galactose, raffinose, and X-gal. The galactose-dependent production of blue-colored patches is indicated as +, whereas white patches are indicated as -. This plate assay is used only for qualitative purposes. A less sensitive reporter, pJK103, was also tested and essentially gave similar results.

LexA fusion protein B42 fusion protein
14-3-3zeta Raf-1 Raf-N Raf-C B42 alone

LexA alone  -  -  -  -  -
WT 14-3-3zeta + + + +  -
Mutant 14-3-3zeta
  K49E +  -  -  -  -
  R56E +  -  -  -  -
  R60E + + + +  -
  K49L +  -  -  -  -
  K49Q + +a + +a  -
  K49R + + + +  -

a The blue color was very weak just above the background.

To quantify the effect of mutations on 14-3-3zeta /Raf interactions, the above experiments were further performed using a quantitative liquid assay. As shown in Fig. 2, 14-3-3zeta bound to the full-length or truncated forms of Raf-1 with different affinities, with Raf-N being strongest and Raf-C weakest (16). Consistent with the above assay, the mutation K49E completely abolished the interaction of 14-3-3zeta with Raf-1, Raf-N, or Raf-C in a parallel fashion. The R56E mutation greatly diminished the interaction, yielding lacZ reporter expression reduced 50-fold compared with the WT protein. The R60E mutation slightly decreased the beta -galactosidase activity (~20-30%). To ensure that the differences in reporter activity among particular combinations of Raf and 14-3-3zeta mutants were not a reflection of differential expression of the mutant 14-3-3 proteins, we tested cells coexpressing Raf with various 14-3-3zeta proteins for the level of each hybrid protein using immunoblotting. As shown in Fig. 2 (lower panels), relative protein levels of WT and mutant 14-3-3zeta proteins as fusion proteins were similar. Stripping and reprobing the membranes with anti-Raf antibody confirmed that similar amounts of Raf were present in all the samples (data not shown). Therefore, it is likely that the impaired reporter gene expression is due to the disrupted 14-3-3zeta /Raf interactions caused by the charge-reversal mutations K49E and R56E.


Fig. 2. Effect of mutations of Lys-49, Arg-56, and Arg-60 of 14-3-3zeta on its interaction with full-length Raf-1 kinase, Raf-N, and Raf-C in yeast. Strains EGY48 harboring pSH18-34, the pEG202 expression vector (carrying LexA-Raf) and the pJG4-5 plasmid (carrying B42-14-3-3zeta or its mutant derivatives) were grown in synthetic medium with galactose. Cells (1 × 107) were collected and divided for the beta -galactosidase assay as described under "Materials and Methods" (upper panels) and for immunoblotting analysis (lower panels). The vertical bars represent relative beta -galactosidase activities expressed (n = 4). The lower panels show the relative levels of the WT and mutant 14-3-3zeta proteins expressed in test strains, and for these experiments, equivalent amounts of total cell protein were analyzed. Anti-hemagglutinin monoclonal antibody (HA.11) was used to probe the B42-14-3-3zeta proteins because an influenza virus hemagglutinin epitope (HA) was inserted between the B42 and 14-3-3zeta sequences in the pJG4-5 vectors. Control strains contain pEG202 (carrying the respective raf genes) in combination with the pJG4-5 plasmid. The expression levels of Raf proteins are similar in all samples.
[View Larger Version of this Image (26K GIF file)]

To confirm the results obtained with the interaction trap system, an alternative in vitro binding assay was performed. For this purpose, WT and mutant 14-3-3 proteins were overexpressed in E. coli as hexahistidine-tagged fusion proteins and immobilized on nickel-charged beads. The binding partner, Raf-1, was expressed and labeled with [35S]methionine using the TNT in vitro transcription-translation system. Equal amounts of radiolabeled Raf-1 protein mixtures were incubated individually with the WT or mutant 14-3-3zeta -coated beads. After extensive washing, Raf-1 protein that was complexed with various 14-3-3 derivatives was visualized following SDS-PAGE separation and autoradiography (Fig. 3A). Consistent with the data obtained with the interaction trap system, K49E abolished the binding of 14-3-3zeta to Raf-1, whereas R56E partially decreased the interactions. R60E bound to Raf as strongly as did the WT protein in this assay.


Fig. 3. Comparison of in vitro binding of Raf-1 kinase to WT and mutant 14-3-3zeta proteins. Transcripts of Raf-1 kinase were generated from the T7 promoter in pHW102. Raf-1 proteins were synthesized in vitro in a rabbit reticulocyte lysate in the presence of [35S]methionine. Equal portions of the labeled Raf protein were incubated with hexahistidine-tagged 14-3-3zeta or mutant derivatives bound to Sepharose beads for 1 h at 4 °C. The immobilized WT or mutant 14-3-3zeta complexes were washed extensively (see "Materials and Methods"), and the bound proteins were eluted with sample buffer, analyzed by SDS-PAGE (12.5%), and visualized using a PhosphorImager. Hexahistidine-tagged beta -galactosidase protein bound to beads was used as a control. 14-3-3zeta /Raf-1 interactions were tested using the mutant 14-3-3zeta proteins K49E, R56E, and R60E (A) or a panel of Lys-49 mutants (B). The amounts of immobilized proteins (beta -galactosidase (beta -Gal) and 14-3-3zeta ) used were revealed by Coomassie Blue staining.
[View Larger Version of this Image (47K GIF file)]

Mutations of Lys-49, Arg-56, and Arg-60 Decrease the Ability of 14-3-3zeta to Activate ExoS

Data from the above experiments suggested the participation of Lys-49 and Arg-56, and possibly Arg-60, in the 14-3-3zeta /Raf interaction. However, it is unknown whether Lys-49 and Arg-56 are specific to the Raf interaction or whether they form part of a general interaction surface for multiple ligands. To address this question, we used a defined biochemical assay, the ExoS activation reaction (11). ExoS is an ADP-ribosyltransferase that catalyzes, in a 14-3-3-dependent manner, the incorporation of the ADP-ribose moiety of the NAD+ molecule into substrates, including Ras, vimentin, and SBTI (11, 42).

For the kinetic studies and protein stability analysis, 14-3-3zeta and its mutants were overexpressed in E. coli BL21(DE3), and individual proteins were purified by nickel chelate affinity chromatography. Hexahistidine tags were removed by enzymatic digestion. The proteins were further purified by gel filtration chromatography on a Superdex 200 column and reached ~95% purity (data not shown).

The recombinant WT 14-3-3zeta protein activated ExoS to ADP-ribosylate SBTI in a dose-dependent manner, with an EC50 of 3.0 nM (Table II). The specific incorporation of ADP-ribose into the substrate SBTI was confirmed by an SDS-PAGE-based assay (see "Materials and Methods"; data not shown). As in the case of Raf binding, K49E drastically increased the EC50 of 14-3-3zeta in the ExoS assay (334 nM; ~110-fold increase), suggesting the decreased affinity of this 14-3-3 mutant toward ExoS. The R56E mutation partially decreased the ability of 14-3-3 to activate ExoS, as measured by the amount of 14-3-3 needed to achieve 50% of Vmax (EC50 ~ 15.9 nM) (Table II). Again, R60E had only a slight effect on ExoS activation. None of these mutants, however, affected the Vmax of the reactions (Table II). Therefore, there is a direct correlation between the effects of mutations of Lys-49, Arg-56, and Arg-60 on interaction with Raf-1 and activation of ExoS.

Table II. Summary of kinetic parameters for ExoS activation by WT and mutant 14-3-3zeta proteins

Assays were performed at 25 °C. Reaction mixtures contained 0.2 M sodium acetate (pH 6.0), 20 nM purified ExoS, 30 µM SBTI, 30 µM NAD+, 1.5 µM bovine serum albumin, and varying concentrations of purified 14-3-3zeta or its mutant proteins. Data were obtained from at least three separate experiments, each performed in triplicate. Relative EC50 was estimated based on the following equation: EC50(mutant)/EC50(WT). Assays were performed at 25 °C. Reaction mixtures contained 0.2 M sodium acetate (pH 6.0), 20 nM purified ExoS, 30 µM SBTI, 30 µM NAD+, 1.5 µM bovine serum albumin, and varying concentrations of purified 14-3-3zeta or its mutant proteins. Data were obtained from at least three separate experiments, each performed in triplicate. Relative EC50 was estimated based on the following equation: EC50(mutant)/EC50(WT).

14-3-3zeta Vmax EC50 Relative EC50

pmol ADP-ribose incorporated nM -fold
WT 5.54  ± 0.64 3.0  ± 0.2 1.0
K49E 5.49  ± 0.70 334  ± 35 111.3
K49L 5.47  ± 0.54 26.1  ± 2.4 8.7
K49Q 5.47  ± 0.59 10.4  ± 0.9 3.5
K49R 5.49  ± 0.58 3.5  ± 0.3 1.2
R56E 5.47  ± 0.56 15.9  ± 1.4 5.3
R60E 5.49  ± 0.61 6.0  ± 0.6 2.0

Panel of Lys-49 Mutations Suggests a Role for the Positive Charge in Ligand Binding

Among three mutants tested above, K49E exhibited the most severe defect in 14-3-3zeta /ligand binding. The nature of the contribution of Lys-49 to ligand binding was further probed by changing Lys-49 to Leu, Gln, or Arg. This panel of Lys-49 mutants was overexpressed in E. coli and purified as described under "Materials and Methods." The effect of these Lys-49 mutations on 14-3-3zeta /ligand binding was investigated using the Raf binding and ExoS activation assays described above. In comparison with K49E, a neutral Leu substitution slightly increased the binding affinity of 14-3-3zeta for Raf as measured in the interaction trap system (Fig. 4) and the in vitro binding assay (Fig. 3B). A polar Gln residue and a positively charged Arg residue significantly restored the binding activity (Fig. 4). The ability of this panel of 14-3-3 mutants to activate ExoS was also examined and was found to increase in the following order in relation to the K49E mutant: K49L < K49Q < K49R (Table II). It appears that a positive charge is important for both Raf binding and ExoS activation. It is interesting that the affinities of the Lys-49 mutants for Raf-1 kinase directly paralleled the efficiencies of ExoS activation, supporting the notion that Raf-1 and ExoS bind to 14-3-3zeta through a common site.


Fig. 4. Effect of mutations of Lys-49 of 14-3-3zeta on its interaction with Raf-1 kinase in yeast. Experiments were carried out essentially as described in the legend to Fig. 2. Interactions of the WT protein and Lys-49 mutants with full-length Raf-1, Raf-N, and Raf-C were tested. The upper panels show the beta -galactosidase activity expressed (n = 4). The lower panels show the relative levels of the 14-3-3zeta fusion proteins expressed. HA, influenza virus hemagglutinin.
[View Larger Version of this Image (21K GIF file)]

K49E, R56E, and R60E Mutations Do Not Result in Gross Structural Changes in 14-3-3zeta

To explore the possibility that the reduced activity of mutant 14-3-3 proteins is a result of structural changes, we probed their structural integrity using several alternative approaches. First, the overall structural integrity of the 14-3-3 mutants was examined by assessing their ability to dimerize. Crystal structure data (29, 30) and other biochemical analyses (43, 44) suggest that 14-3-3 proteins function as a dimer. We found that dimer formation can be demonstrated in vivo using the interaction trap system (Table I). This observation provided a simple means to evaluate the relative conformational integrity of the mutant proteins in vivo because dimer formation depends on the integrity of the folded proteins (45). Despite specific defects in association with Raf-1 and activation of ExoS, each of the 14-3-3 mutants readily formed dimers with the WT (Table I) and mutant (data not shown) partners in vivo. In vitro, the purified 14-3-3 mutant proteins comigrated with the WT protein, as a dimer, on a native gel2 and on a gel filtration column (Superdex 75 HR10/30) (data not shown). These data suggest that the Lys-49 mutations, R56E, and R60E caused no drastic perturbation to the overall structure of the proteins.

Second, the relative stability of the mutant proteins compared with that of WT 14-3-3zeta was evaluated by analysis of the proteins' resistance to limited proteolytic digestion with chymotrypsin. Purified WT 14-3-3zeta and its mutant derivatives were incubated with chymotrypsin for 30 min, followed by analysis of the digestion products by SDS-PAGE and silver staining. The mutant proteins gave similar digestion patterns compared with WT 14-3-3zeta (Fig. 5), suggesting that the global structure of each mutant protein was not altered. Similar results were obtained using additional proteases, including Pronase and carboxypeptidase B. 


Fig. 5. Comparison of partial protease digestion patterns of WT and mutant 14-3-3zeta proteins. 2.5 µg of purified 14-3-3zeta proteins were incubated with 0.5 unit of chymotrypsin for 30 min at 37 °C. Digested proteins were separated on SDS-PAGE (15%) and revealed by silver staining.
[View Larger Version of this Image (49K GIF file)]

Third, as a quantitative measure of the possible structural effect of the mutations, we used CD spectroscopy to compare the overall secondary structure of the mutant 14-3-3 proteins with that of the WT protein. Consistent with the three-dimensional crystal structure (29, 30) and earlier reports (46), the far-UV CD spectra of 14-3-3zeta proteins were characteristic of an alpha -helical structure (Fig. 6). Ellipticity minima were observed near 208 and 222 nm. As shown in Fig. 6, the Lys-49 mutations, R56E, and R60E resulted in virtually no effect on the CD spectrum of 14-3-3zeta , suggesting that these mutations do not alter the global secondary structure of 14-3-3zeta . Because K49E causes the most dramatic reduction in 14-3-3zeta /ligand binding, we further compared the chemical stability of the K49E mutant and the WT protein as measured by CD at 222 nm. Strikingly, the K49E mutant, which disrupted the 14-3-3zeta /Raf interaction and drastically decreased the affinity for ExoS, was as stable as the WT protein as judged by the guanidine hydrochloride-induced unfolding profiles. The midpoint denaturation concentrations and the concentration intervals in which chemical denaturation took place did not change for K49E proteins (WT: Cm = 1.31 ± 0.10 M, Delta C = 0.25 ± 0.03 M; K49E: Cm = 1.35 ± 0.13 M, Delta C = 0.21 ± 0.05 M). Similarly, no change in the Cm and Delta C values of other Lys-49 mutants was observed. Taken together, the data presented above strongly support the notion that the mutations K49E, K49L, K49Q, K49R, R56E, and R60E do not induce large structural alterations of 14-3-3zeta .


Fig. 6. Far-UV CD spectra of WT and mutant 14-3-3zeta proteins. CD spectra were generated at 25 °C using 0.4 mg/ml protein in phosphate-buffered saline.
[View Larger Version of this Image (23K GIF file)]


DISCUSSION

14-3-3 proteins interact with diverse proteins involved in a wide range of biological systems (1). Based on our crystal structure data, we proposed that 14-3-3zeta binds to multiple ligands through a conserved amphipathic groove (30). On the charged face of the groove, three positively charged residues (Lys-49, Arg-56, and Arg-60) are lined along alpha -helix 3. Here, we report that charge-reversal mutations at these three positions disrupted the interaction of 14-3-3zeta with Raf-1 kinase and ExoS to different degrees, with K49E being the most dramatic. The disruption of the 14-3-3zeta /ligand interaction by mutations of Lys-49 appears to be due to the local alteration of the charge property at this position, rather than mutation-induced structural change. More important, our work identifies a critical residue, Lys-49, with general importance for ligand binding, which is consistent with the crystal structure model. In addition, application of a panel of Lys-49 mutations establishes a clear correlation between the disruption of 14-3-3zeta /Raf association and the 14-3-3zeta /ExoS interaction, suggesting that diverse associated proteins use a common binding site on 14-3-3zeta . In further support of this notion, the effective association of 14-3-3zeta with the N-terminal fragment of c-Bcr kinase (encoded by the first exon) was also disrupted by the K49E mutation (data not shown).

Lys-49 appears to be part of a binding interface in which multiple residues are involved. Clearly, Arg-56 also contributes to ligand binding because the charge-reversal mutation of Arg-56 partially decreased the binding of 14-3-3zeta to Raf and ExoS. Only a slight effect of the R60E mutation on ligand binding was observed. The mechanism by which Lys-49 contributes to ligand binding was investigated by replacing the initial charge-reversal mutation residue (Glu) with Leu, Gln, or Arg. It appears that the hydrophobic nature of the Lys-49 side chain is not the primary determinant for 14-3-3 binding since a hydrophobic Leu residue showed only a slight effect. The ability of 14-3-3zeta to bind Raf was partially restored with the elimination of the negative charge and the introduction of Gln or Arg, suggesting that the positive charge of Lys-49 is involved in the association of 14-3-3 with Raf kinase. However, at this point, we cannot rule out the possibility that Lys-49 is indirectly involved in ligand binding, for example, by interacting with residues in the C-terminal loop of the 14-3-3zeta protein. In our crystal structure, the C-terminal 12 amino acid residues form a poorly ordered structure and appear lined in the proposed ligand-binding groove (30).

Drastic deletion analysis of 14-3-3zeta implicates a different region of the protein in ligand binding. Luo et al. (47) reported the importance of the C-terminal sequence (amino acids 179-245) of 14-3-3zeta in the binding of Raf-1 kinase in COS cells. Interestingly, only the inactive form of Raf kinase was found associated with this C-terminal 14-3-3 fragment, and the active Raf form was complexed only with the full-length 14-3-3 protein. A C-terminal fragment of 14-3-3zeta (residues 166-208; termed BoxI) was also found to be necessary and sufficient for association with phosphorylated tyrosine hydroxylase (48). However, Liu et al. (20) found that deletion of the N-terminal sequence, which abolished dimer formation, also impaired the binding of 14-3-3tau to Raf, Cbl, and p85 (phosphatidylinositol 3-kinase). It is possible that the N-terminal sequence directly or indirectly participates in ligand binding. It is also conceivable that an initial contact at the Lys-49 region may induce a conformational change that is required to expose the primary binding site in the C-terminal fragment of 14-3-3.

The data presented here support the notion that 14-3-3zeta uses the conserved amphipathic groove for binding to multiple ligands, which include Raf, Bcr, and ExoS. A complementary amphipathic conformation in the ligand may permit the specific interaction of 14-3-3zeta with diverse associated proteins. For instance, the phosphorylation in ligands may provide part of the charged interface for 14-3-3 binding since 14-3-3 has been shown to bind only to phosphorylated ligands in a number of cases (7, 23, 31, 49, 50). Such a mode of action is reminiscent of the mechanism proposed for calmodulin, another highly conserved protein that can bind a range of regulatory proteins (see Ref. 51 for review). Calmodulin adopts an amphipathic structure that forms a binding site for amphipathic helices. Besides the amphipathic structure, 14-3-3 shares several additional features with calmodulin. For example, they are both highly conserved, abundant, and ubiquitous eukaryotic proteins. Both interact with a range of diverse proteins and enzymes, including kinases and hydroxylases. In addition, the binding of Ca2+/calmodulin or 14-3-3 to target proteins alters their activity, although the role of 14-3-3 binding, in many cases, is unclear. Such similarities between 14-3-3 and calmodulin raise the possibility that 14-3-3, like calmodulin, may regulate the activity of the associated proteins directly. Evidence is accumulating. The first example is the stimulatory role of 14-3-3 for tyrosine and tryptophan hydroxylases after phosphorylation by Ca2+/calmodulin-dependent kinase II (6). 14-3-3 has also been found to inhibit (8) or activate (9) protein kinase C and serves as an obligatory activator of ExoS ADP-ribosyltransferase (11). Interestingly, 14-3-3 proteins serve as inhibitors of nitrate reductase from spinach leaves in a phosphorylation-dependent manner (52). However, a direct role of 14-3-3 in Raf kinase activation seems unlikely because the addition of purified 14-3-3 to the Raf protein has no significant effect (12, 24, 25, 31).

14-3-3 proteins have been shown to interact with Raf kinases and are implicated in Raf-mediated signal transduction. Earlier experiments have demonstrated that 14-3-3 binds to Raf via multiple sites. In support of this notion, two phosphorylation-dependent high affinity binding sites in Raf have been identified, which are the N-terminal regulatory domain sequence containing Ser-259 and the C-terminal kinase domain sequence containing Ser-621 (49). Consistent with these data, we show here that 14-3-3zeta can bind independently to the Raf-N and Raf-C fragments (Fig. 2). Moreover, the point mutation K49E abolished the binding of 14-3-3zeta to either Raf-N or Raf-C. We conclude that Raf-N and Raf-C utilize a similar structural determinant on 14-3-3zeta for binding that involves Lys-49. Such an interaction could enable a single 14-3-3 dimer to bind to the N- and C-terminal domains of the same Raf molecule simultaneously or to bind to two molecules of Raf. Alternatively, it also allows one 14-3-3 dimer to tether one molecule of Raf and another 14-3-3-associated partner together.

Because Lys-49 is conserved among all 14-3-3 isoforms, Lys-49 equivalent residues in other isoforms may also participate in ligand binding in a similar fashion. However, isoform specificity and ligand specificity issues have not been addressed by current studies. It is possible that residues that are not conserved in 14-3-3 and/or binding sequences in the target proteins confer different levels of binding specificity.


FOOTNOTES

*   This work was supported in part by National Institutes of Health Grant GM53165 and the University Research Committee of Emory University (to H. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   Contributed equally to this work.
Dagger Dagger    Recipient of the Burroughs Wellcome Fund New Investigator Award in the Basic Pharmacological Sciences and a faculty development award from the Pharmaceutical Research and Manufacturers of America Foundation. To whom correspondence should be addressed: Dept. of Pharmacology, Emory University School of Medicine, 1510 Clifton Rd. N. E., Atlanta, GA 30322. Tel.: 404-727-0368; Fax: 404-727-0365; E-mail: haianfu{at}bimcore.emory.edu.
1   The abbreviations used are: ExoS, exoenzyme S from P. aeruginosa; X-gal, 5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside; PAGE, polyacrylamide gel electrophoresis; SBTI, soybean trypsin inhibitor; WT, wild-type.
2   S. Masters, L. Zhang, and H. Fu, unpublished results.

ACKNOWLEDGEMENTS

We thank Joe Barbieri for kindly providing ExoS, Roger Brent for vectors of the interaction trap system, and Tom Roberts for anti-Raf antibody. We thank Todd Milne and Hongzhu Yang for critical reading of the manuscript; Keith Wilkinson, Dale Edmonson, Shane Masters, and Romesh Subramanian for valuable discussions; and Susan Qu for assistance in CD experiments.


REFERENCES

  1. Aitken, A. (1996) Trends Cell Biol. 6, 341-347 [CrossRef]
  2. Moore, B. W., and Perez, V. J. (1967) in Physiological and Biochemical Aspects of Nervous Integration (Carlson, F. D., ed), pp. 343-359, Prentice-Hall, Englewood Cliffs, NJ
  3. Ford, J. C., al-Khodairy, F., Fotou, E., Sheldrick, K. S., Griffiths, D. J., and Carr, A. M. (1994) Science 265, 533-535 [Medline] [Order article via Infotrieve]
  4. van Heusden, G. P., Griffiths, D. J., Ford, J. C., Chin, A. W. T. F., Schrader, P. A., Carr, A. M., and Steensma, H. Y. (1995) Eur. J. Biochem. 229, 45-53 [Abstract]
  5. Gelperin, D., Weigle, J., Nelson, K., Roseboom, P., Irie, K., Matsumoto, K., and Lemmon, S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11539-11543 [Abstract]
  6. Ichimura, T., Isobe, T., Okuyama, T., Yamauchi, T., and Fujisawa, H. (1987) FEBS Lett. 219, 79-82 [CrossRef][Medline] [Order article via Infotrieve]
  7. Ichimura, T., Isobe, T., Okuyama, T., Takahashi, N., Araki, K., Kuwano, R., and Takahashi, Y. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7084-7088 [Abstract]
  8. Toker, A., Ellis, C. A., Sellers, L. A., and Aitken, A. (1990) Eur. J. Biochem. 191, 421-429 [Abstract]
  9. Isobe, T., Hiyane, Y., Ichimura, T., Okuyama, T., Takahashi, N., Nakajo, S., and Nakaya, K. (1992) FEBS Lett. 308, 121-124 [CrossRef][Medline] [Order article via Infotrieve]
  10. Meller, N., Liu, Y., Collins, T. L., Bonnefoy-Berard, N., Baier, G., Isakov, N., and Altman, A. (1996) Mol. Cell. Biol. 16, 5782-5791 [Abstract]
  11. Fu, H., Coburn, J., and Collier, R. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2320-2324 [Abstract]
  12. Fu, H., Xia, K., Pallas, D. C., Cui, C., Conroy, K., Narsimhan, R. P., Mamon, H., Collier, R. J., and Roberts, T. M. (1994) Science 266, 126-129 [Medline] [Order article via Infotrieve]
  13. Morrison, D. (1994) Science 266, 56-57 [Medline] [Order article via Infotrieve]
  14. Freed, E., Symons, M., Macdonald, S. G., McCormick, F., and Ruggieri, R. (1994) Science 265, 1713-1716 [Medline] [Order article via Infotrieve]
  15. Irie, K., Gotoh, Y., Yashar, B. M., Errede, B., Nishida, E., and Matsumoto, K. (1994) Science 265, 1716-1719 [Medline] [Order article via Infotrieve]
  16. Fantl, W. J., Muslin, A. J., Kikuchi, A., Martin, J. A., MacNicol, A. M., Gross, R. W., and Williams, L. T. (1994) Nature 371, 612-614 [CrossRef][Medline] [Order article via Infotrieve]
  17. Reuther, G. W., Fu, H., Cripe, L. D., Collier, R. J., and Pendergast, A. M. (1994) Science 266, 129-133 [Medline] [Order article via Infotrieve]
  18. Conklin, D. S., Galaktionov, K., and Beach, D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7892-7896 [Abstract]
  19. Bonnefoy-Berard, N., Liu, Y. C., von Willebrand, M., Sung, A., Elly, C., Mustelin, T., Yoshida, H., Ishizaka, K., and Altman, A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10142-10146 [Abstract]
  20. Liu, Y. C., Elly, C., Yoshida, H., Bonnefoy-Berard, N., and Altman, A. (1996) J. Biol. Chem. 271, 14591-14595 [Abstract/Free Full Text]
  21. Pallas, D. C., Fu, H., Haehnel, L. C., Weller, W., Collier, R. J., and Roberts, T. M. (1994) Science 265, 535-537 [Medline] [Order article via Infotrieve]
  22. Vincenz, C., and Dixit, V. M. (1996) J. Biol. Chem. 271, 20029-20034 [Abstract/Free Full Text]
  23. Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S. T. (1996) Cell 87, 619-628 [Medline] [Order article via Infotrieve]
  24. Suen, K. L., Bustelo, X. R., and Barbacid, M. (1995) Oncogene 11, 825-831 [Medline] [Order article via Infotrieve]
  25. Li, S., Janosch, P., Tanji, M., Rosenfeld, G. C., Waymire, J. C., Mischak, H., Kolch, W., and Sedivy, J. M. (1995) EMBO J. 14, 685-696 [Abstract]
  26. Dent, P., Jelinek, T., Morrison, D. K., Weber, M. J., and Sturgill, T. W. (1995) Science 268, 1902-1906 [Medline] [Order article via Infotrieve]
  27. Farrar, M. A., Alberol, I., and Perlmutter, R. M. (1996) Nature 383, 178-181 [CrossRef][Medline] [Order article via Infotrieve]
  28. Luo, Z., Tzivion, G., Belshaw, P. J., Vavvas, D., Marshall, M., and Avruch, J. (1996) Nature 383, 181-185 [CrossRef][Medline] [Order article via Infotrieve]
  29. Xiao, B., Smerdon, S. J., Jones, D. H., Dodson, G. G., Soneji, Y., Aitken, A., and Gamblin, S. J. (1995) Nature 376, 188-191 [CrossRef][Medline] [Order article via Infotrieve]
  30. Liu, D., Bienkowska, J., Petosa, C., Collier, R. J., Fu, H., and Liddington, R. (1995) Nature 376, 191-194 [CrossRef][Medline] [Order article via Infotrieve]
  31. Michaud, N. R., Fabian, J. R., Mathes, K. D., and Morrison, D. K. (1995) Mol. Cell. Biol. 15, 3390-3397 [Abstract]
  32. Studier, F. W., and Moffatt, B. A. (1986) J. Mol. Biol. 189, 113-130 [Medline] [Order article via Infotrieve]
  33. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1987) Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York
  34. Gyuris, J., Golemis, E., Chertkov, H., and Brent, R. (1993) Cell 75, 791-803 [Medline] [Order article via Infotrieve]
  35. Deng, W. P., and Nickoloff, J. A. (1992) Anal. Biochem. 200, 81-88 [Medline] [Order article via Infotrieve]
  36. Fields, S., and Song, O. (1989) Nature 340, 245-246 [CrossRef][Medline] [Order article via Infotrieve]
  37. Kulich, S. M., Frank, D. W., and Barbieri, J. T. (1993) Infect. Immun. 61, 307-313 [Abstract]
  38. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  39. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354 [Abstract]
  40. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  41. Estojak, J., Brent, R., and Golemis, E. A. (1995) Mol. Cell. Biol. 15, 5820-5829 [Abstract]
  42. Coburn, J. (1992) Curr. Top. Microbiol. Immunol. 175, 133-143 [Medline] [Order article via Infotrieve]
  43. Boston, P. F., Jackson, P., Kynoch, P. A., and Thompson, R. J. (1982) J. Neurochem. 38, 1466-1474 [Medline] [Order article via Infotrieve]
  44. Jones, D. H., Ley, S., and Aitken, A. (1995) FEBS Lett. 368, 55-58 [CrossRef][Medline] [Order article via Infotrieve]
  45. Jones, D. H., Martin, H., Madrazo, J., Robinson, K. A., Nielsen, P., Roseboom, P. H., Patel, Y., Howell, S. A., and Aitken, A. (1995) J. Mol. Biol. 245, 375-384 [CrossRef][Medline] [Order article via Infotrieve]
  46. Robinson, K., Jones, D., Patel, Y., Martin, H., Madrazo, J., Martin, S., Howell, S., Elmore, M., Finnen, M. J., and Aitken, A. (1994) Biochem. J. 299, 853-861 [Medline] [Order article via Infotrieve]
  47. Luo, Z. J., Zhang, X. F., Rapp, U., and Avruch, J. (1995) J. Biol. Chem. 270, 23681-23687 [Abstract/Free Full Text]
  48. Ichimura, T., Uchiyama, J., Kunihiro, O., Ito, M., Horigome, T., Omata, S., Shinkai, F., Kaji, H., and Isobe, T. (1995) J. Biol. Chem. 270, 28515-28518 [Abstract/Free Full Text]
  49. Muslin, A. J., Tanner, J. W., Allen, P. M., and Shaw, A. S. (1996) Cell 84, 889-897 [Medline] [Order article via Infotrieve]
  50. Liao, J., and Omary, M. B. (1996) J. Cell. Biol. 133, 345-357 [Abstract]
  51. Finn, B. E., and Forsen, S. (1995) Structure 3, 7-11 [Medline] [Order article via Infotrieve]
  52. Bachmann, M., Huber, J. L., Liao, P. C., Gage, D. A., and Huber, S. C. (1996) FEBS Lett. 387, 127-131 [CrossRef][Medline] [Order article via Infotrieve]
  53. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Proteins Struct. Funct. Genet. 11, 281-296 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.